The Phase 2 obesity trial reported −17.1% mean weight change at 48 weeks in the combined 4 mg groups. The sponsor’s TRIUMPH-1 efficacy analysis reported −19.0% at 80 weeks in the 4 mg arm.
Same number, different protocols
The time points, protocols and populations differ. The second figure should not be treated as a continuation of the first cohort or as a calculation of additional weight loss between weeks 48 and 80.
How to interpret the evidence
Use the trial names alongside the amounts. A shared target amount alone does not make the findings directly comparable.
This series reports assigned research arms for interpreting study results. Retatrutide is investigational, and clinical-trial amounts are not dosing instructions.